CD40LG and Hyperglycemia: Similarly to NOD-SCID recipients of E42 pancreatic tissue, when treated with alloxan 4 mo after transplantation, four out of seven grafted C57BL/6 mice treated biweekly for up to 4 mo post-transplant with CTAL4-Ig and anti-CD40L were able to sustain normal blood glucose levels, while all non-grafted alloxan-treated C57BL/6 mice exhibited irreversible hyperglycemia (8.5 ± 1.3 versus 31 ± 1.9 mmol/l,p < 0.001).